ARTICLE SUMMARY:
Name any category of heart failure innovation in the last 25 years, and cardiologist William Abraham has been involved in bringing it forward. From his new role as chief medical officer at Cardiac Dimensions, he shares his insights on future directions in heart failure, and the increasingly prominent role the device industry will play.
Cardiac Dimensions—currently conducting pivotal clinical trials of the Carillon Mitral Contour System, a differentiated therapy for functional mitral regurgitation—recently gained the endorsement of prominent heart failure clinician William Abraham, MD, who joined the long-standing start-up as chief medical officer in September. (See “Cardiac Dimensions: On the Brink of an Expanding Opportunity in Mitral Valves,” MedTech Strategist, July–August 2023).
This marks Abraham’s second operational role in industry. After six years as chair of the strategic advisory board of V-Wave, he became that start-up’s chief medical officer in 2019, guiding clinical trials of a novel minimally invasive interatrial shunt—a pioneering intervention in a new category of heart failure therapy. In August 2024, Johnson & Johnson acquired V-Wave, paying $600 million up front, with the potential total deal value reaching $1.7 billion contingent on regulatory and commercial milestones.
